MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Treatment

The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.

Annals of Surgical Oncology 2019 February 24 [Link] Lewis GD, Dalwadi SM, Farach A, Brian Butler E, Teh BS Abstract BACKGROUND: Pleural mesothelioma is a rare but aggressive form of cancer. Local recurrence represents the majority of treatment failures and overall survival (OS) outcomes remain dismal. Adding locoregional treatment with radiotherapy after surgical resection has […]

Comments Off on The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.

Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”

Current Treatment Options in Oncology 2019 February 21 [Link] Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D’Argento E Abstract Unresectable or relapsed malignant pleural mesothelioma (MPM) has dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog allows a modest survival benefit, […]

Comments Off on Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Genome Medicine 2019 February 18 [Link] Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen […]

Comments Off on BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Journal of Clinical Oncology 2019 February 20 [Link] Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV Abstract PURPOSE: Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that […]

Comments Off on Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.

International Journal of Nanomedicine 2019 January 23 [Link] Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is […]

Comments Off on Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.

Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.

Casopis Lekaru Ceskych 2019 Winter [Link] Klos D, Riško J, Stašek M, Loveček M, Hanuliak J, Skalický P, Lemstrová R, Mohelníková BD, Študentová H, Neoral Č, Melichar B. The tumors of the peritoneal surface, both primary and secondary, are associated with a very poor prognosis and rapid progression through conventional oncology treatment including systemic chemotherapy, […]

Comments Off on Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

British Journal of Cancer 2019 February 11 [Link] Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R16, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G Abstract BACKGROUND: The Mesothelioma Avastin Cisplatin Pemetrexed […]

Comments Off on MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy.

Cureus 2018 November 28 [Link] Kitajima K, Nakamichi T, Hasegawa S, Kuribayashi K, Yamakado K Abstract Talc pleurodesis has been reported to increase fluorodeoxyglucose (FDG) uptake in the high attenuation areas of pleural thickening, making it difficult to distinguish between benign granulomatous inflammatory processes and malignancies, which may therefore interfere with the post-chemotherapy disease evaluation […]

Comments Off on Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy.

Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Anticancer Research 2019 February [Link] Salo SAS, Ilonen I, Laaksonen S, Myllärniemi M, Salo JA, Rantanen T Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPeM) is a rare type of cancer with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. Treatment and survival of patients with MPeM have […]

Comments Off on Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.

BMC Cancer 2019 January 30 [Link] Borchert S1, Wessolly M2, Schmeller J2, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a tumour arising from pleural cavities with poor prognosis. Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. The reasons for the […]

Comments Off on Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.